Longevity escape velocity · 2026 evidence update
Longevity escape velocity: the evidence in 2026
A partial-reprogramming therapy has entered human testing. The field now faces the harder tests of functional benefit, durability, systemic delivery and repeatability.
Longevity escape velocity, or LEV, is the point at which successive medical advances would increase remaining healthy life expectancy by more than one year during each year that passes. A therapy that adds time once would be progress. LEV requires that gains keep arriving, remain safe, work across the causes of aging and reach people soon enough to compound.
A partial-reprogramming therapy entered human testing
In March 2026, an early Phase 1 study began testing ER-100 in adults with glaucoma or non-arteritic anterior ischemic optic neuropathy. The study plans to enroll up to 18 people and follow them for five years. Its primary purpose is safety and tolerability after a single dose.
ER-100 is the first human test of this particular epigenetic-reprogramming approach. The study addresses a localized eye treatment and measures safety. Evidence about longer life, slower whole-body aging and systemic effects will require later studies with different endpoints.
Established: a first-in-human safety trial is recruiting. Unknown: whether the treatment improves vision, produces durable benefit or can be applied safely beyond the eye.
ClinicalTrials.gov NCT07290244, updated May 19, 2026 ↗The strongest rejuvenation signals remain preclinical
Recent work has expanded the experimental base. A 2026 mouse study reported that locally delivered OSK factors altered age-linked methylation patterns and improved cartilage measures in osteoarthritis models. Another 2026 study built human microphysiological systems that reproduce aspects of tissue aging and may allow faster screening of candidate interventions.
These advances improve targeting and experimental measurement. Translation into human medicine will depend on whole-body safety, reduced illness, preserved function and longer healthy life.
Established: cells, tissue models and animals can show rejuvenation-like changes. Inferred: better models may improve candidate selection. Unknown: whether those changes translate into meaningful, lasting human outcomes.
Experimental & Molecular Medicine: local OSK delivery in mouse osteoarthritis models, 2026 ↗ Nature Biomedical Engineering: human microphysiological aging systems, 2026 ↗Biomarkers must connect to clinical outcomes
A biomarker can move while disease risk, function and lifespan remain unchanged. The evidence chain has to connect a biological mechanism to clinical benefit, characterize harms, show how long the effect lasts and establish whether treatment can be repeated.
The regulatory problem is also unresolved. The U.S. Food and Drug Administration currently lacks a simple aging indication with an established surrogate endpoint. Sponsors proposing effects across multiple conditions need evidence and trial designs that support those claims.
A credible LEV claim would need durable human outcomes across more than one tissue, repeatable treatment, acceptable long-term risk and gains that continue to arrive faster than aging removes them.
National Institute on Aging: FDA review of geroscience-related applications ↗The next decade will test a portfolio of platforms
The plausible path combines localized reprogramming, removal or control of harmful senescent cells, immune restoration, replacement of damaged cells and tissues, and better measures of function and biological change. Each route addresses a different part of the problem and carries different risks.
The near-term signals are replicated functional benefit, persistent effects and controlled delivery beyond a single tissue. Those results would move LEV from a serious hypothesis toward an evidence-backed trajectory.
Practical implication: plan around established prevention and medical care while tracking the experimental evidence separately.
Nature Aging: replacement as an aging intervention, 2025 ↗ NIA Fifth Geroscience Summit agenda: endpoints, biomarkers and trials, 2026 ↗